EVENTS | VIEW CALENDAR
IO Summit 2018 Show Preview: Informing immuno-oncology
Cambridge Healthtech Institute
Sixth Annual Immuno-Oncology Summit
August 27–31, 2018
Boston, Seaport World Trade Center
Be Boston-bound for erudition in the newest science, technology and techniques in cancer immunotherapy
So what’s new for the Immuno-Oncology Summit in 2018? Cambridge Healthtech Institute (CHI) notes that the summit now has a track on bispecific antibodies, as well as a new neoantigen-targeted therapies track, which highlights personalized immunotherapy approaches. Immuno-oncology (IO) biomarkers coverage has been expanded to three days in order to cover predictive biomarkers, companion diagnostics and immune profiling, and coverage of adoptive T cell therapy has been expanded to three days to span discovery and development.
With an expanded exhibit hall and a new “Partnering Forum” to highlight emerging companies and investment opportunities, there’s plenty of opportunity to acquire new information, according to CHI, which emphasizes that the annual meeting focuses on the latest applied research. The comprehensive five-day, 12-track program covers immunomodulatory antibody engineering, emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic viruses and personalized cancer vaccines.
“The Immuno-Oncology Summit brings together a unique and international mix of large and medium pharmaceutical and biotech companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the summit a perfect meeting place to share experience, foster collaborations across industry and academia and evaluate emerging technologies,” CHI notes of the event. “Now in its sixth year, the IO Summit consistently delivers a cutting-edge agenda, 600-plus senior delegates and a sold-out exhibit hall. Please join us in Boston for comprehensive scientific coverage and unparalleled networking opportunities.”
Also among the highlights this year is the plenary keynote session, which kicks off on Tuesday, Aug. 28, at 4:15 p.m. Dr. Jennifer Brogdon, the director of the Exploratory Immuno-Oncology operations at Novartis, will present “CAR-T Therapy for B Cell Malignancies,” followed by “Walking on the Moon: Reflections on the Work of the Cancer Moonshot and the Future of the Biden Cancer Initiative” by Dr. Gregory C. Simon, president of the Biden Cancer Initiative.
Immunomodulatory Therapeutic Antibodies for Cancer
Emerging Targets, Combinations and Antibody Engineering for Next-Generation Immunotherapy
Rational Combination Cancer Immunotherapy
Data Drives Combinatorial Strategies and Successes
Immuno-Oncology Biomarkers 1
Quantitative Immune Profiling and Immune Monitoring
Oncolytic Virus Immunotherapy
Commercializing the Exciting Potential of Oncolytic Virotherapy
Training Seminar 1
CAR-T Engineering for Protein Scientists
Dr. Dina Schneider of Lentigen Technology Inc.
Bispecific Antibodies for Cancer Immunotherapy
Engineering Next-Generation Biotherapeutics in Immuno-Oncology
Preclinical and Translational Immuno-Oncology
Predictive Preclinical Models and Translational Strategies for Cancer Immunotherapy
Immuno-Oncology Biomarkers 2
Predictive Biomarkers and Companion Diagnostics
Adoptive T Cell Therapy 1: Discovery
Engineering Immune Cells for More Effective Immunotherapies
Training Seminar 2
Immunology for Drug Discovery Scientists
Dr. Masha Fridkis-Hareli and Dr. Tatiana Novobrantseva of Verseau Therapeutics
Emerging Immuno-Oncology Targets
Novel Targets and Pathways for Cancer Immunotherapy and Combinations
Personalized Cancer Vaccines
Neoantigen Targeted Therapies
Personalized Cancer Immunotherapy in the Genomic Era
Adoptive T Cell Therapy 2: Development
Case Studies and Clinical Progress of CAR, NK, TCR, and TIL
Immuno-Oncology Investing & Partnering Forum
Facilitating Partnering, Funding & Investment to Advance Immuno-Oncology Drugs
Dinner Short Courses
(separate registration required)
Tuesday, August 28
6:30 p.m. to 9 p.m.
Short Course 1: Bioinformatics for Immuno-Oncology and Translational Research
Dr. Yuriy Gusev of Georgetown University
Short Course 2: Next-Generation Immunotherapies: Part 1
A two-part dinner workshop series featuring presentations on the latest immunotherapy technologies from emerging companies. Learn about engineering the next-generation immunotherapies coming down the pipeline, including bi-specific and multi-specific antibody constructs, fully recombinant antibody prodrugs, innovative multivalent therapeutics, immunotherapeutic fusion proteins, antibody-drug conjugates and other innovative approaches.
Wednesday, August 29
6 p.m. to 9 p.m.
Short Course 3: Next-Generation Immunotherapies: Part 2
Highlighting emerging companies
The Immuno-Oncology Investing and Partnering Forum will play host to an “Emerging Company Showcase” as part of the program agenda. This showcase allows immuno-oncology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs and executives in the field.
Cambridge Healthtech Training Seminars offer real-life case studies, problems encountered/solutions applied and extensive coverage of the basic science underlying each topic. Experienced training seminar instructors offer a mix of formal lectures, interactive discussions and activities to help attendees maximize their learning experiences. These immersive trainings will be of value to scientists from industry and academic research groups who are entering new fields—and to those working in supporting roles that will benefit from an in-depth briefing on a specific aspect of the industry.
The exhibit hall will be open Tuesday, Aug. 29, from 10 a.m. to 6:30 p.m., with the welcome reception taking place during the final hour; Wednesday, Aug. 29, from 10 a.m. to 4 p.m.; and Thursday, Aug. 30, from 10 a.m. to 10:45 a.m., just before exhibitors need to begin dismantling their areas.